Latham & Watkins represented the initial purchasers in the offering. Stem, Inc. executed its US$400 million aggregate principal amount of 0.50% Green Convertible Senior Notes due 2028 in […]
Stem’s $400 Million Green Convertible Senior Notes Offering
Pyxis Oncology’s $168 Million Upsized Initial Public Offering
Latham & Watkins represented the underwriters in the offering. Pyxis Oncology, Inc., a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target […]
Dole’s $400 Million Initial Public Offering
Skadden, Arps, Slate, Meagher & Flom, working closely to Arthur Cox, represented Dole in the offering, while Latham & Watkins represented the underwriters. Dole plc, a newly […]
Sight Sciences’ $240 Million Initial Public Offering
Latham & Watkins LLP represented Sight Sciences, Inc. in the offering, while Davis Polk advised the representatives of the several underwriters. Sight Sciences, Inc. executed its initial public […]
Alpha Tau’s Business Combination with Healthcare Capital Corp.
Latham & Watkins LLP represented Alpha Tau in the transaction, while Winston & Strawn represented the placement agent. Alpha Tau Medical Limited, the developer of the […]
SQZ Biotechnologies’ $60 Million Common Stock Offering
Latham & Watkins LLP represented SQZ Biotechnologies Company in the transaction. SQZ Biotechnologies Company (NYSE: SQZ) (SQZ), a cell therapy company developing novel treatments for multiple […]
Nano-X Imaging’s Secondary Public Offering
Latham & Watkins LLP represented the underwriters in the offering. NANO-X IMAGING LTD (NASDAQ: NNOX), an innovative medical imaging technology company, has announced that it has […]